Key points There have been significant advances in both inhalation medicines and delivery
devices with “intelligent nebulisers” and “dry-powder inhalers” becoming commonplace in …

In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been
proven to be highly effective. Consequently, an increasing number of drugs and devices …

Cystic fibrosis (CF) is the most common autosomal recessive disease in Caucasians
associated with early death. Although the faulty gene is expressed in epithelia throughout …

The life expectancy of people with cystic fibrosis (CF), a lethal inherited disease, has been
greatly extended by advances in therapy. Currently, there are a number of potential drugs for …

Introduction: Cystic fibrosis (CF) is a multisystem genetic disorder, which usually results in
significant respiratory dysfunction. At present there is no cure for CF, but advances in …

Abstract Treatment of cystic fibrosis lung disease has developed from an understanding of
the abnormal airway surface liquid resulting from a lack of function of the cystic fibrosis …

Chronic bacterial infection is one of the key challenges in caring for patients with cystic
fibrosis (CF). Effective infection control requires appropriate administration of antibiotics …

Inhalation of antipseudomonal antibiotics is a cornerstone in treating cystic fibrosis patients.
It has shown to be effective in slowing down the process of pulmonary deterioration and …

Nebulised therapies are extensively used in the daily therapeutic management of cystic
fibrosis both for mucociliary clearance and for the management of chronic infections …

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics …